Concordance of SARS-CoV-2 Antibody Results during a Period of Low Prevalence

Author:

Miller Cheryl N.1ORCID,Althoff Keri N.2,Schlueter David J.34,Anton-Culver Hoda5,Chen Qingxia4,Garbett Shawn4,Ratsimbazafy Francis4,Thomsen Isaac6,Karlson Elizabeth W.7,Cicek Mine8,Pinto Ligia A.1ORCID,Malin Bradley A.4,Ohno-Machado Lucila9,Williams Carolyn10,Goldstein David11,Kouame Aymone4,Ramirez Andrea12,Gebo Kelly A.13,Schully Sheri D.12

Affiliation:

1. Frederick National Laboratory for Cancer Research, National Cancer Institute, Frederick, Maryland, USA

2. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA

3. National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, USA

4. Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, Tennessee, USA

5. Department of Medicine, School of Medicine, University of California, Irvine, Irvine, California, USA

6. Department of Pediatrics, Division of Infectious Diseases, Vanderbilt University Medical Center, Nashville, Tennessee, USA

7. Harvard Medical School, Brigham and Women’s Hospital, Boston, Massachusetts, USA

8. Mayo Clinic, Rochester, Minnesota, USA

9. Department of Biomedical Informatics, University of California—San Diego Health, La Jolla, California, USA

10. National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, Maryland, USA

11. Columbia University Medical Center, New York, New York, USA

12. All of Us Research Program, National Institutes of Health, Bethesda, Maryland, USA

13. Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

Abstract

What is the agreement of commercial SARS-CoV-2 immunoglobulin G (IgG) assays during a time of low coronavirus disease 2019 (COVID-19) prevalence and no vaccine availability? Serological tests produced concordant results in a time of low SARS-CoV-2 prevalence and no vaccine availability, driven largely by the proportion of samples that were negative by two immunoassays. The CDC recommends two sequential tests for positivity for future pandemic preparedness.

Funder

HHS | NIH | National Cancer Institute

HHS | NIH | NIH Office of the Director

HHS | NIH | NIH Clinical Center

Publisher

American Society for Microbiology

Subject

Molecular Biology,Microbiology

Reference23 articles.

1. US Food and Drug Administration. 2020. EUA authorized serology test performance. US Food and Drug Administration, Silver Spring, MD. https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance.

2. A Trans-Governmental Collaboration to Independently Evaluate SARS-CoV-2 Serology Assays

3. Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19)

4. Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019

5. Persistence of SARS-CoV-2-specific B and T cell responses in convalescent COVID-19 patients 6–8 months after the infection

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3